EA200900517A1 - Use of erythropoietin for the treatment of myeloid leukemia - Google Patents

Use of erythropoietin for the treatment of myeloid leukemia

Info

Publication number
EA200900517A1
EA200900517A1 EA200900517A EA200900517A EA200900517A1 EA 200900517 A1 EA200900517 A1 EA 200900517A1 EA 200900517 A EA200900517 A EA 200900517A EA 200900517 A EA200900517 A EA 200900517A EA 200900517 A1 EA200900517 A1 EA 200900517A1
Authority
EA
Eurasian Patent Office
Prior art keywords
erythropoietin
treatment
myeloid leukemia
myeloblastic leukemia
relates
Prior art date
Application number
EA200900517A
Other languages
Russian (ru)
Other versions
EA013806B1 (en
Inventor
Николай Маркович Поздеев
Олег Олегович Кузнецов
Сергей Сергеевич Михайлов
Юрий Васильевич Зиновьев
Николай Васильевич Рябов
Надежда Станиславовна Федоровская
Елена Львовна Назарова
Original Assignee
Общество С Ограниченной Ответственностью "Лэнс-Фарм"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Лэнс-Фарм" filed Critical Общество С Ограниченной Ответственностью "Лэнс-Фарм"
Priority to EA200900517A priority Critical patent/EA013806B1/en
Publication of EA200900517A1 publication Critical patent/EA200900517A1/en
Publication of EA013806B1 publication Critical patent/EA013806B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области медицины и касается применения эритропоэтина, в частности эритропоэтина-бета, для лечения миелобластного лейкоза, в частности перевивного миелобластного лейкоза, а также оптимальной схемы такого применения. Эритропоэтин является эффективным средством, расширяющим возможности лечения и улучшающим результаты терапии миелобластного лейкоза.The invention relates to the field of medicine and relates to the use of erythropoietin, in particular erythropoietin-beta, for the treatment of myeloblastic leukemia, in particular transplantable myeloblastic leukemia, as well as the optimal regimen of such use. Erythropoietin is an effective means of expanding treatment options and improving the results of treatment of myeloblastic leukemia.

EA200900517A 2009-04-01 2009-04-01 Use of erythropoetin for treating myeloblast leukosis EA013806B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA200900517A EA013806B1 (en) 2009-04-01 2009-04-01 Use of erythropoetin for treating myeloblast leukosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA200900517A EA013806B1 (en) 2009-04-01 2009-04-01 Use of erythropoetin for treating myeloblast leukosis

Publications (2)

Publication Number Publication Date
EA200900517A1 true EA200900517A1 (en) 2010-08-30
EA013806B1 EA013806B1 (en) 2010-08-30

Family

ID=42779156

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900517A EA013806B1 (en) 2009-04-01 2009-04-01 Use of erythropoetin for treating myeloblast leukosis

Country Status (1)

Country Link
EA (1) EA013806B1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein

Also Published As

Publication number Publication date
EA013806B1 (en) 2010-08-30

Similar Documents

Publication Publication Date Title
CY1122186T1 (en) CANCER TREATMENT METHODS
EA201690785A1 (en) NEW COMBINED THERAPY OF ACUTE MYELOID LEUKEMIA (AML)
EA201101521A1 (en) METHODS OF TREATMENT OF ONCOLOGICAL DISEASES, USING EPIMETABOLIC SWITCHES, MULTIPLE-DIFFERENT INTRACELLULAR MOLECULES OR IMPACT FACTORS
EA201390772A1 (en) NEW SALTS AND POLYMORPHIC FORMS OF AFATINIBA
EA201890333A1 (en) ANTI-VIRUS COMPOUNDS
EA201590987A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
EA201491447A1 (en) ENDINES, THEIR CONJUGATES AND METHODS FOR THEIR RECEPTION AND APPLICATION
EA201590868A1 (en) ANTI-VIRUS COMPOUNDS
EA201590997A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
EA201492002A1 (en) ANTI-VIRUS COMPOUNDS
EA201490853A1 (en) ANTI-VIRUS COMPOUNDS
EA201390274A1 (en) Boron-containing small molecules
EA201590748A1 (en) ANTI-VIRUS CONNECTIONS AGAINST RSV
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
EA201400976A1 (en) BENZODIOXANES IN COMBINATION WITH OTHER ACTIVE MEANS TO INHIBIT LEUKOTRIEN PRODUCTION
EA201391274A1 (en) AMINOHINOLINES AS KINAZ INHIBITORS
EA201391019A1 (en) CONNECTIONS AND METHODS FOR KINAZ MODULATION AND ALSO THE INDICATIONS TO THEIR APPLICATION
EA201491811A1 (en) ANTI-LgR5 ANTIBODIES AND IMMUNOCONJUGATES
EA201290980A1 (en) DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBURONIC ACID
EA201391644A1 (en) PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS FOR THEIR RECEPTION AND APPLICATION
EA201270254A1 (en) DERIVATIVES OF 5-FLUOROPYRIMIDINON
EA201391127A1 (en) C-17 AND C-3 MODIFIED TRITERPENOIDS WITH INHIBITOR ACTIVITY OF HIV MATURATION
EA201291300A1 (en) DERIVATIVES OF NAFT-2-LUCUS ACID FOR THE TREATMENT OF AIDS
EA201491623A1 (en) SUBSTITUTED PYRROLIDIN-2-CARBOXAMIDES
EA201170356A1 (en) POLYMORPHIC AND AMORPHOUS FORMS OF LACOSAMIDE AND AMORPHOUS COMPOSITIONS

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU